Srs Capital Advisors, Inc. Inozyme Pharma, Inc. Transaction History
Srs Capital Advisors, Inc.
- $977 Million
- Q2 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 475 shares of INZY stock, worth $2,384. This represents 0.0% of its overall portfolio holdings.
Number of Shares
475Holding current value
$2,384% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding INZY
# of Institutions
92Shares Held
52.4MCall Options Held
17.6KPut Options Held
2.7K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.73MShares$28.8 Million0.05% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$22.6 Million18.06% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$21.5 Million1.06% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.94MShares$19.8 Million0.31% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.7MShares$18.6 Million0.51% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $202M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...